Celularity
Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.
Founded
2016Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.
Celularity, founded in Florham Park, N.J., is a clinical-stage biotechnology company at the forefront of cellular medicine. The company's core mission is to harness the regenerative power of the postpartum placenta to develop and commercialize advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies. Celularity's vision is to revolutionize treatment for aging-related diseases, degenerative conditions, cancer, and immune disorders through scalable and high-quality therapeutic solutions.
Notable affiliated individuals include Dr. Robert Hariri, a pioneer in the field of cellular medicine. Celularity has attracted significant investment from prominent entities such as Sorrento Therapeutics and United Therapeutics. Key achievements include its listing on NASDAQ under the ticker CELU and the development of a robust pipeline of therapeutic programs. The company's impact lies in its innovative approach to leveraging placental biology to address critical medical needs, potentially transforming the landscape of regenerative medicine.
Companies similar to Celularity include Platelet BioGenesis, Cell BioEngines, Cellular Approaches and HebeCell.
Celularity was founded in 2016.
Celularity's headquarters is located in Florham Park, NJ, US.
Celularity's most recent funding round was for $30M (USD) in May 2022.
As of May 26, 2022, Celularity has raised a total of $400M (USD).
Celularity has 225 employees as of Feb 6, 2024.
Cellular Approaches
